Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRDF 
Cardiff Oncology Inc (CRDF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CRDF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.07
1 Year Target Price $10.07
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 68.18% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 136.38M USD | Price to earnings Ratio - | 1Y Target Price 10.07 |
Price to earnings Ratio - | 1Y Target Price 10.07 | ||
Volume (30-day avg) 7 | Beta 1.28 | 52 Weeks Range 1.90 - 5.64 | Updated Date 09/15/2025 |
52 Weeks Range 1.90 - 5.64 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -12212.4% |
Management Effectiveness
Return on Assets (TTM) -47.9% | Return on Equity (TTM) -91.93% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 66606000 | Price to Sales(TTM) 250.24 |
Enterprise Value 66606000 | Price to Sales(TTM) 250.24 | ||
Enterprise Value to Revenue 122.21 | Enterprise Value to EBITDA -3.66 | Shares Outstanding 66525900 | Shares Floating 64895971 |
Shares Outstanding 66525900 | Shares Floating 64895971 | ||
Percent Insiders 6.05 | Percent Institutions 39.68 |
Upturn AI SWOT
Cardiff Oncology Inc
Company Overview
History and Background
Cardiff Oncology, Inc. (CRDF) is a clinical-stage biotechnology company focused on developing therapies targeting cancer vulnerabilities in RAS-mutated tumors, initially focusing on KRAS G12D mutations. Founded as Trovagene, Inc. they later rebranded and shifted focus to oncology.
Core Business Areas
- Clinical Development: Focuses on developing onvansertib, a polo-like kinase 1 (PLK1) inhibitor, for various cancers with KRAS mutations.
Leadership and Structure
The leadership team is headed by Mark Erlander, Ph.D., as Chief Executive Officer. The company has a typical organizational structure for a clinical-stage biotech, with departments focused on research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Onvansertib: Onvansertib is an investigational, highly selective, orally bioavailable inhibitor of PLK1. It's being evaluated in various clinical trials targeting cancers harboring KRAS mutations. Market share is currently 0% as it is not yet FDA approved. Competitors include companies developing KRAS inhibitors, such as Mirati Therapeutics and Amgen, and other PLK1 inhibitors.
Market Dynamics
Industry Overview
The oncology market is vast and competitive, with a significant unmet need for effective therapies targeting RAS-mutated cancers. KRAS mutations are prevalent in many cancer types, making it a high-value target.
Positioning
Cardiff Oncology is positioned as a player in the targeted therapy space, specifically focusing on PLK1 inhibition to address KRAS-mutated cancers. Their competitive advantage relies on the efficacy and safety profile of onvansertib in ongoing clinical trials.
Total Addressable Market (TAM)
The TAM for KRAS-mutated cancer therapies is estimated to be in the billions of dollars annually. Cardiff Oncology is attempting to penetrate that market by targeting PLK1.
Upturn SWOT Analysis
Strengths
- Targeting unmet needs in RAS-mutated cancers
- Promising early clinical data for onvansertib
- Experienced management team
Weaknesses
- Single product pipeline
- Dependence on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Potential for FDA approval of onvansertib
- Expansion into other cancer indications
- Partnerships or acquisitions by larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from other KRAS inhibitors
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRTX
- AMGN
- LLY
Competitive Landscape
Cardiff Oncology faces competition from established pharmaceutical companies with approved KRAS inhibitors. Their competitive advantage will rely on demonstrating superior efficacy and safety with onvansertib.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical and clinical development milestones rather than revenue generation.
Future Projections: Future growth is contingent on successful clinical trial results for onvansertib and potential FDA approval. Analyst estimates vary widely based on perceived probability of success.
Recent Initiatives: Recent initiatives include advancing onvansertib through clinical trials, exploring new cancer indications, and securing additional funding.
Summary
Cardiff Oncology is a clinical-stage company focusing on KRAS-mutated cancers. Its success hinges on the clinical development of onvansertib, a PLK1 inhibitor. The company needs to show good data in its trials, but it faces competition from major players in the space. A large opportunity lies in a possible take over due to small market cap.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cardiff Oncology Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cardiff Oncology Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-07-27 | CEO & Director Dr. Mark Erlander Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 32 | Website https://www.cardiffoncology.com |
Full time employees 32 | Website https://www.cardiffoncology.com | ||
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.